said Armando Anido.

Auxilium completes individual enrollment in XIAFLEX stage III trial against Peyronie’s disease Auxilium Pharmaceuticals, Inc begin to work . ‘We are happy to do this important advancement milestone in Peyronie’s disease and progress what can potentially be considered a second indication for XIAFLEX,’ said Armando Anido, CEO and President of Auxilium. ‘We believe completing the enrollment of over 600 individuals at sites in the U.S. And Australia in under half a year speaks to the enthusiasm in the urology community and their potential patients for a nonsurgical treatment alternate.

up to 40 mg

The mid and high dose organizations demonstrated a statistically significant improvement in the looks of cellulite, as measured by GAIS ratings, with a p-worth of <0.05 in comparison to placebo for both endpoints. In the mid and high dosage groupings, 68 % of sufferers reported being 'Pleased' or 'Extremely Satisfied' with the outcomes of their treatment, in comparison to just 34 % of individuals randomized to placebo. Positive and constant outcomes were also demonstrated over the trial's other endpoints, including Patient and Doctor assessed Composite Responder Analyses.